Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07230353
PHASE1

A Phase 1b Open-label Study to Evaluate Safety in Participants With Rheumatoid Arthritis

Sponsor: Xencor, Inc.

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine the safety and tolerability of XmAb13676 in patients with rheumatoid arthritis. Participants will be given XmAb13676 subcutaneously (SC) by injection under the skin.

Official title: A Phase 1b, Open-label, Dose-Escalation Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Plamotamab in Participants With Rheumatoid Arthritis

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

47

Start Date

2025-10-21

Completion Date

2028-06

Last Updated

2025-11-17

Healthy Volunteers

No

Interventions

BIOLOGICAL

XmAb13676

Biological

Locations (4)

Arensia Research Clinic

Tbilisi, Georgia

Xencor Investigative Site

Tbilisi, Georgia

Arensia Research Clinic

Chisinau, Moldova

Xencor Investigative Site

Auckland, New Zealand